Boone Capital Increases Stake in HealthEquity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HQY?
Source: Fool
- New Investment Highlight: According to a SEC filing dated February 17, 2026, Boone Capital Management purchased 212,856 shares of HealthEquity for $19,499,738, bringing its stake to 6.12%, indicating a bullish outlook on the healthcare financial services sector.
- Market Performance Analysis: As of February 17, 2026, HealthEquity's share price stood at $74.36, down 34.3% year-over-year, significantly underperforming the S&P 500 by 45.93 percentage points, reflecting market caution regarding its future growth prospects.
- Financial Health Status: HealthEquity reported a 7% year-over-year increase in health savings accounts (HSAs) to 10.6 million for the fiscal year ending January 31, 2026, demonstrating its competitive position and solid customer base in the market.
- Profitability Improvement: In the third quarter of fiscal 2026, HealthEquity achieved sales of $322.2 million, a 7.9% increase from the previous year, with net income soaring from $5.7 million to $51.7 million, showcasing the company's strong profitability even amidst challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HQY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HQY
Wall Street analysts forecast HQY stock price to rise
11 Analyst Rating
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 76.790
Low
89.00
Averages
117.09
High
129.00
Current: 76.790
Low
89.00
Averages
117.09
High
129.00
About HQY
HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boone Capital Increases Stake in HealthEquity
- New Investment Highlight: According to a SEC filing dated February 17, 2026, Boone Capital Management purchased 212,856 shares of HealthEquity for $19,499,738, bringing its stake to 6.12%, indicating a bullish outlook on the healthcare financial services sector.
- Market Performance Analysis: As of February 17, 2026, HealthEquity's share price stood at $74.36, down 34.3% year-over-year, significantly underperforming the S&P 500 by 45.93 percentage points, reflecting market caution regarding its future growth prospects.
- Financial Health Status: HealthEquity reported a 7% year-over-year increase in health savings accounts (HSAs) to 10.6 million for the fiscal year ending January 31, 2026, demonstrating its competitive position and solid customer base in the market.
- Profitability Improvement: In the third quarter of fiscal 2026, HealthEquity achieved sales of $322.2 million, a 7.9% increase from the previous year, with net income soaring from $5.7 million to $51.7 million, showcasing the company's strong profitability even amidst challenges.
See More
Boone Capital Acquires HealthEquity Shares Worth $19.5 Million
- Share Acquisition: Boone Capital Management disclosed in an SEC filing dated February 17, 2026, that it purchased 212,856 shares of HealthEquity for a transaction value of $19.5 million, indicating a bullish outlook on the company.
- Asset Allocation: This acquisition positions HealthEquity at 6.12% of Boone Capital's reportable assets under management, although it has fallen out of the fund's top five holdings by value.
- Performance Metrics: HealthEquity reported Q3 fiscal 2026 sales of $322.2 million, a 7.3% increase year-over-year, with net income soaring from $5.7 million to $51.7 million, highlighting its robust growth potential in the healthcare financial services sector.
- Market Trends: Despite a 34.3% decline in HealthEquity's stock price over the past year, hitting a 52-week low of $72.76 on February 17, the number of health savings accounts grew by 7% year-over-year to 10.6 million, suggesting a positive outlook for future financial results.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Investor Focus: When considering buying Micron Technology (MU) stock, analysts' opinions are particularly crucial, and investors should pay attention to these rating changes to make informed investment choices.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a thorough market insight.
- Market Impact: Adjustments in analysts' ratings not only affect the performance of individual stocks but may also create fluctuations in overall market sentiment, prompting investors to closely monitor these changes to seize investment opportunities.
See More
White House Unveils Healthcare Plan to Slash Drug Prices and Transform Industry Dynamics
- Drug Price Reform: The White House's unveiling of 'The Great Healthcare Plan' on January 15, 2026, aims to significantly reduce prescription drug prices through 'Most-Favored-Nation' pricing agreements, alleviating consumer burdens and reshaping the pharmaceutical market landscape.
- Subsidy Shift: By redirecting insurance subsidies directly to consumers instead of insurers, the plan is expected to lower insurance costs and enhance consumer choice, thereby impacting the revenue models of traditional insurance companies.
- Retail Pharmacy Gains: The proposal to allow more prescription drugs to be sold over-the-counter will directly boost sales for retail pharmacies like Walmart, increasing foot traffic and enhancing the profitability of their clinic operations.
- Portfolio Reevaluation: Investors are advised to reassess their ETF portfolios, prioritizing companies that benefit from the new policies, such as HealthEquity and the iShares U.S. Pharmaceuticals ETF, while avoiding middlemen companies facing regulatory pressures.
See More
HealthEquity Inc (HQY) Shares Oversold with RSI at 28.8
- Oversold Signal: HealthEquity Inc (HQY) shares dropped to $84.505 on Monday, with an RSI of 28.8, indicating that the recent heavy selling may be exhausting, potentially providing entry points for bullish investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 67.4, HQY's 28.8 RSI suggests relative weakness, which may attract investors looking for undervalued opportunities.
- Historical Performance: HQY's 52-week low is $74.07 and high is $116.65, with the current trading price of $84.55 reflecting its performance within this range, prompting a reassessment by investors.
- Investor Sentiment: While the stock is currently oversold, investors should cautiously evaluate market trends to avoid making impulsive decisions in an uncertain market environment.
See More
US Stock Market Rallies, S&P 500 Hits All-Time High
- Strong Labor Market: The US unemployment rate fell to 4.4% in December, below the expected 4.5%, indicating labor market resilience and boosting investor confidence in economic recovery.
- Wage Growth Exceeds Expectations: Average hourly earnings rose 3.8% year-over-year in December, surpassing the 3.6% forecast, which not only enhances consumer spending power but also supports economic growth.
- Consumer Confidence Rebounds: The University of Michigan's January consumer sentiment index increased to 54.0, exceeding expectations of 53.5, suggesting growing optimism among consumers about the economic outlook, potentially driving future consumption.
- Global Market Synchronization: European and Chinese stock markets rallied in tandem, contributing to gains in the US stock market, reflecting the potential for global economic recovery and further enhancing investor risk appetite.
See More
Boone Capital Increases Stake in HealthEquity
- New Investment Highlight: According to a SEC filing dated February 17, 2026, Boone Capital Management purchased 212,856 shares of HealthEquity for $19,499,738, bringing its stake to 6.12%, indicating a bullish outlook on the healthcare financial services sector.
- Market Performance Analysis: As of February 17, 2026, HealthEquity's share price stood at $74.36, down 34.3% year-over-year, significantly underperforming the S&P 500 by 45.93 percentage points, reflecting market caution regarding its future growth prospects.
- Financial Health Status: HealthEquity reported a 7% year-over-year increase in health savings accounts (HSAs) to 10.6 million for the fiscal year ending January 31, 2026, demonstrating its competitive position and solid customer base in the market.
- Profitability Improvement: In the third quarter of fiscal 2026, HealthEquity achieved sales of $322.2 million, a 7.9% increase from the previous year, with net income soaring from $5.7 million to $51.7 million, showcasing the company's strong profitability even amidst challenges.
See More
Boone Capital Acquires HealthEquity Shares Worth $19.5 Million
- Share Acquisition: Boone Capital Management disclosed in an SEC filing dated February 17, 2026, that it purchased 212,856 shares of HealthEquity for a transaction value of $19.5 million, indicating a bullish outlook on the company.
- Asset Allocation: This acquisition positions HealthEquity at 6.12% of Boone Capital's reportable assets under management, although it has fallen out of the fund's top five holdings by value.
- Performance Metrics: HealthEquity reported Q3 fiscal 2026 sales of $322.2 million, a 7.3% increase year-over-year, with net income soaring from $5.7 million to $51.7 million, highlighting its robust growth potential in the healthcare financial services sector.
- Market Trends: Despite a 34.3% decline in HealthEquity's stock price over the past year, hitting a 52-week low of $72.76 on February 17, the number of health savings accounts grew by 7% year-over-year to 10.6 million, suggesting a positive outlook for future financial results.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Investor Focus: When considering buying Micron Technology (MU) stock, analysts' opinions are particularly crucial, and investors should pay attention to these rating changes to make informed investment choices.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a thorough market insight.
- Market Impact: Adjustments in analysts' ratings not only affect the performance of individual stocks but may also create fluctuations in overall market sentiment, prompting investors to closely monitor these changes to seize investment opportunities.
See More
White House Unveils Healthcare Plan to Slash Drug Prices and Transform Industry Dynamics
- Drug Price Reform: The White House's unveiling of 'The Great Healthcare Plan' on January 15, 2026, aims to significantly reduce prescription drug prices through 'Most-Favored-Nation' pricing agreements, alleviating consumer burdens and reshaping the pharmaceutical market landscape.
- Subsidy Shift: By redirecting insurance subsidies directly to consumers instead of insurers, the plan is expected to lower insurance costs and enhance consumer choice, thereby impacting the revenue models of traditional insurance companies.
- Retail Pharmacy Gains: The proposal to allow more prescription drugs to be sold over-the-counter will directly boost sales for retail pharmacies like Walmart, increasing foot traffic and enhancing the profitability of their clinic operations.
- Portfolio Reevaluation: Investors are advised to reassess their ETF portfolios, prioritizing companies that benefit from the new policies, such as HealthEquity and the iShares U.S. Pharmaceuticals ETF, while avoiding middlemen companies facing regulatory pressures.
See More
HealthEquity Inc (HQY) Shares Oversold with RSI at 28.8
- Oversold Signal: HealthEquity Inc (HQY) shares dropped to $84.505 on Monday, with an RSI of 28.8, indicating that the recent heavy selling may be exhausting, potentially providing entry points for bullish investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 67.4, HQY's 28.8 RSI suggests relative weakness, which may attract investors looking for undervalued opportunities.
- Historical Performance: HQY's 52-week low is $74.07 and high is $116.65, with the current trading price of $84.55 reflecting its performance within this range, prompting a reassessment by investors.
- Investor Sentiment: While the stock is currently oversold, investors should cautiously evaluate market trends to avoid making impulsive decisions in an uncertain market environment.
See More
US Stock Market Rallies, S&P 500 Hits All-Time High
- Strong Labor Market: The US unemployment rate fell to 4.4% in December, below the expected 4.5%, indicating labor market resilience and boosting investor confidence in economic recovery.
- Wage Growth Exceeds Expectations: Average hourly earnings rose 3.8% year-over-year in December, surpassing the 3.6% forecast, which not only enhances consumer spending power but also supports economic growth.
- Consumer Confidence Rebounds: The University of Michigan's January consumer sentiment index increased to 54.0, exceeding expectations of 53.5, suggesting growing optimism among consumers about the economic outlook, potentially driving future consumption.
- Global Market Synchronization: European and Chinese stock markets rallied in tandem, contributing to gains in the US stock market, reflecting the potential for global economic recovery and further enhancing investor risk appetite.
See More
